BetaFor now, only select medications are available to compare. This data is sourced from the medication label and is not exhaustive.
efficacy
ACR20 Response at Week 24 - Adults
Study 1 (TNFi-naive): 58%; Study 2 (TNFi-experienced): 53%
Study 1 (Mixed population; 31% TNFi-experienced): 51%
ACR50 Response at Week 24 - Adults
Study 1 (TNFi-naive): 40%; Study 2 (TNFi-experienced): 35%
Study 1 (Mixed population; 31% TNFi-experienced): 35%
ACR30 Response at Week 12 - Pediatric
Not approved for pediatric PsA
JPsA: 91% (31/34 patients)
ACR50 Response at Week 12 - Pediatric
Not approved for pediatric PsA
JPsA: 91% (31/34 patients)
Review efficacy data to choose the clinically appropriate treatment for your patient
safety
Black Box Warning
None
None
Contraindications
Serious hypersensitivity reaction to ixekizumab or any excipients
Serious hypersensitivity reaction to secukinumab or any excipients
Most Common Adverse Reactions (≥1%)
injection site reactions, upper respiratory tract infections, nausea, tinea infections
nasopharyngitis, diarrhea, upper respiratory tract infection
indications
Adult Psoriatic Arthritis
Yes
Yes
Pediatric Psoriatic Arthritis
No
Yes (≥2 years, ≥15 kg)
Adult Plaque Psoriasis (≥6 years, moderate-to-severe)
Yes
Yes
Adult Ankylosing Spondylitis
Yes
Yes
Adult Non-radiographic Axial Spondyloarthritis
Yes
Yes
Pediatric Enthesitis-Related Arthritis
No
Yes (≥4 years, ≥15 kg)
Adult Hidradenitis Suppurativa
No
Yes
Coverage
Add insurance carrier above to get more details about the coverage for each medication
dosing
Adult PsA - Dosing
160 mg (two 80 mg injections) at Week 0, then 80 mg every 4 weeks (no higher dose option specified)
Subcutaneous: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg every 4 weeks OR 150 mg every 4 weeks (without loading); 300 mg every 4 weeks if continued active PsA
Adult PsA with Coexistent Moderate-to-Severe PsO
Use adult plaque psoriasis dosing regimen ((160 mg at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks)
Use plaque psoriasis dosing regimen (300 mg at Weeks 0, 1, 2, 3, and 4, then 300mg every 4 weeks)
Adult PsA - Intravenous Option
Not available
With loading: 6 mg/kg at Week 0, then 1.75 mg/kg every 4 weeks (max 300 mg per infusion); Without loading: 1.75 mg/kg every 4 weeks
Pediatric PsA (2+ years, ≥15 kg)
Not approved
≥15 kg to <50 kg: 75 mg at Weeks 0, 1, 2, 3, 4, then every 4 weeks; ≥50 kg: 150 mg at Weeks 0, 1, 2, 3, 4, then every 4 weeks
Administration
Adults: Subcutaneous injection only
Adults: Subcutaneous injection or intravenous infusion; Pediatric: Subcutaneous injection only
pharmacology
Mechanism of Action
Humanized IgG4 monoclonal antibody that selectively binds IL-17A
Human IgG1 monoclonal antibody that selectively binds IL-17A
Half-life
Mean half-life: 13 days
Mean half-life: 22-31 days
Immunogenicity
PsA Population: 11% developed anti-drug antibodies, 8% had confirmed neutralizing antibodies (up to 52 weeks)
Across all populations: Less than 1% developed anti-drug antibodies, approximately 8% had neutralizing antibodies (up to 52 weeks)
Find savingsView All ProgramsView All Programs
Coverage Not Required
$25Taltz (ixekizumab)Out-of-pocket costs with copay card
$9200 Anual CapCoverage Not Required
Cost estimate not availableCosentyx (secukinumab)